CG Oncology, Inc.
CGON
$63.67
-$0.79-1.22%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 39.38% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 39.38% | -- | |||
| Cost of Revenue | 12.11% | -5.97% | |||
| Gross Profit | -10.47% | 11.29% | |||
| SG&A Expenses | -22.89% | 34.03% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.36% | 8.32% | |||
| Operating Income | 4.75% | -4.90% | |||
| Income Before Tax | 5.70% | -5.75% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 5.70% | -5.75% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 5.70% | -5.75% | |||
| EBIT | 4.75% | -4.90% | |||
| EBITDA | 5.64% | -4.38% | |||
| EPS Basic | 9.62% | -5.04% | |||
| Normalized Basic EPS | 9.61% | -5.03% | |||
| EPS Diluted | 9.62% | -5.04% | |||
| Normalized Diluted EPS | 9.61% | -5.03% | |||
| Average Basic Shares Outstanding | 4.34% | 0.66% | |||
| Average Diluted Shares Outstanding | 4.34% | 0.66% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||